58267-85-9

Basic information

• Product Name: 4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL
• Synonyms: RARECHEM AL BP 0179;2-(4-BROMOTHIENYL)-1,3-DIOXOLANE;4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL;2-(4-Bromothien-2-yl)-1,3-dioxolane;2-(4-bromothiophen-2-yl)-1,3-dioxolane;1,3-Dioxolane, 2-(4-bromo-2-thienyl)-
• CAS NO: 58267-85-9
• Molecular Formula: C₇H₇BrO₂S
• Molecular Weight: 235.1
• Product Categories: Building Blocks;Halogenated;Thiophene
• Mol File: 58267-85-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 290.8 °C at 760 mmHg
• Flash Point: 129.7 °C
• Appearance: /
• Density: 1.671 g/cm³
• Vapor Pressure: 0.00352mmHg at 25°C
• Refractive Index: 1.591
• CAS DataBase Reference: 4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL(58267-85-9)
• EPA Substance Registry System: 4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL(58267-85-9)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 58267-85-9(Hazardous Substances Data)

Usage

General Description

4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL is a chemical compound that is commonly used as a building block in organic synthesis. It is a derivative of 4-bromothiophene, which is a heterocyclic compound with a sulfur atom in its ring structure. The addition of the carboxaldehyde and ethylene glycol acetal groups to the thiophene ring increases its reactivity and allows for it to be used in a wide range of chemical reactions. 4-BROMOTHIOPHENE-2-CARBOXALDEHYDE ETHYLENE GLYCOL ACETAL is often employed in the pharmaceutical and agrochemical industries for the production of various drugs and crop protection agents. Additionally, it has potential uses in material science for the development of new materials with custom-designed properties.

InChI:InChI=1/C7H7BrO2S/c8-5-3-6(11-4-5)7-9-1-2-10-7/h3-4,7H,1-2H2

Upstream product

• 18791-75-8 4-Bromothiophen-2-aldehyde 
• 107-21-1 ethylene glycol 

Downstream Products

• 18812-38-9 4-iodothiophene-2-carbaldehyde 
• 89324-44-7 3-carboxy-thiophene-5-carboxaldehyde 
• 175592-59-3 (5‐formylthiophen‐3‐yl)boronic acid 

Relevant articles and documents

Organic small molecular semiconductor material containing anthracene dithiophene as well as preparation method and application thereof

The invention discloses an organic small molecular semiconductor material containing anthracene dithiophene as well as a preparation method and an application thereof. The structural formula of the material is as shown in a formula I, wherein the unit A is an electron deficient group; R1 is hydrogen or alkyl with 1-30 carbon atoms or a group in the alkyl with 1-30 carbon atoms, one or more of which are replaced by halogen atoms, oxygen atoms, alkenyl, alkynyl, aryl, hydroxyl, amino, carboxyl, ester groups, cyan or nitryl. The material has unique advantages of relatively good light capturing ability, proper electronic energy level, relatively high electronic mobility and the like, and is applied to organic solar battery apparatuses as an electron acceptor material to obtain good apparatus performances.

Four and ring kinase inhibitors

The invention belongs to the technical field of medicines and relates to a tetra-cyclo-kinase inhibitor shown in the general formula (I) and its pharmaceutically acceptable salt, stereisomer, ester or solvate. In the general formula (I), R1, R2, R3, R4, M, W, X, Y and Z are defined in the specification. The invention also relates to a preparation method of the compounds, a drug containing the compounds, and a use of the compounds and its pharmaceutically acceptable salt, stereisomer, ester or solvate in preparation of a drug for treating and/or preventing ALK-mediated cancer-related diseases.

Four and circular Anaplastic lymphoma kinase inhibitors

The invention belongs to the technical field of medicines, and particularly relates to a four-ring anaplastic lymphoma kinase inhibitor as shown in a general formula (I), or stereisomers, or pharmaceutically acceptable salts, esters or solvates of the inhibitor, wherein A1, A2, A3, M, X, Y, Q, R4, R5, R6, R7 and n are defined in the specification. The invention also relates to a preparation method of these compounds, pharmaceutical preparations and pharmaceutical compositions containing these compounds, and application of the compound or the stereisomers, or the pharmaceutically acceptable salts, esters or solvates of the compound in preparation of medicines for treating and/or preventing ALK-mediated cancer related diseases.